title: Non-invasive glioblastoma immunoprofiling by printed peptide arrays.
abstract: Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker.
authors.affiliation: Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg , Heidelberg, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Mock
authors.affiliation: Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg , Heidelberg, Germany.
authors.forename: Christel
authors.initials: C
authors.lastname: Herold-Mende
keywords: Antibodies; TNC; glioblastoma; long-term survival; non-invasive; biomarker; serum